AstraZeneca UK Limited
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$572.5M
Doctors Paid
2,006
Transactions
29,182
2024 Total
$114.9M
Payment Breakdown by Category
Research$497.4M (86.9%)
Royalty/License$57.5M (10.0%)
Consulting$12.8M (2.2%)
Travel$3.1M (0.5%)
Food & Beverage$310,662 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $497.4M | 14,798 | 86.9% |
| Royalty or License | $57.5M | 24 | 10.0% |
| Consulting Fee | $12.8M | 4,940 | 2.2% |
| Travel and Lodging | $3.1M | 3,791 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 240 | 0.3% |
| Food and Beverage | $310,662 | 5,389 | 0.1% |
Payments by Type
Research
$497.4M
14,798 transactions
General
$75.1M
14,384 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | $65.3M | 0 | 375 |
| A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 | $20.5M | 0 | 63 |
| A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | $19.2M | 8 | 1,821 |
| A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 | $18.2M | 0 | 68 |
| A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION | $12.6M | 0 | 158 |
| The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus | $12.5M | 6 | 898 |
| AZD2693, Cardiovascular, Renal and Metabolism | $12.2M | 0 | 70 |
| a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma | $9.9M | 0 | 29 |
| This is a multiple dose randomized parallel double blind double dummy multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400 Formoterol Fumarate AB FF 12 compared to individual components and Tiotropium 18 when administered to patients with stable chronic obstructive pulmonary disease COPD | $9.2M | 1 | 229 |
| A Phase 2b multicentre randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of zibotentan and dapagliflozin in patients with chronic kidney disease with estimated glomerular filtration rate eGFR between 20 and 60 mL min 1.73 m2 | $8.6M | 0 | 182 |
| A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck | $8.2M | 0 | 135 |
| A Phase II Randomized Openlabel Multicenter Doseranging Study in Adults and Pediatric Individuals 2265 12 years of Age to Assess the Safety Immunogenicity Pharmacokinetics and Pharmacodynamics of AZD7442 a Combination Product of Two Monoclonal Antibodies Tixagevimab and Cilgavimab for Pre-exposure Prophylaxis of COVID19 | $6.8M | 0 | 59 |
| iMED Oncology project- Sarah Cannon Research Institute Agreemet | $6.8M | 0 | 84 |
| Dapagliflozin in Acute Decompensated Heart Failure | $6.5M | 0 | 3 |
| A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | $6.3M | 0 | 113 |
| A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) | $6.1M | 0 | 6 |
| A Phase Ib/II open-label, multi-center study of the safety and efficacy of IMCgp100 in combination with MEDI4736 or tremelimumab or the combination of MEDI4736 and tremelimumab compared to IMCgp100 alone in patients with advanced melanoma | $6.0M | 0 | 43 |
| CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | $5.6M | 0 | 80 |
| A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease | $5.5M | 0 | 128 |
| A Randomized Double-blind Placebo-controlled Study of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects with Parkinsons Disease | $5.4M | 0 | 25 |
| MAJIC A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | $5.1M | 0 | 30 |
| A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer | $4.8M | 0 | 554 |
| A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction Persistent Inflammation and Elevated N terminal Prohormone Brain Natriuretic Peptide | $4.3M | 0 | 94 |
| A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer | $4.3M | 2 | 92 |
| The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE | $4.2M | 3 | 174 |
| A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | $3.8M | 0 | 212 |
| The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE | $3.8M | 5 | 134 |
| A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma | $3.7M | 0 | 142 |
| Observational Study of Obstructive Lung Disease NOVELTY | $3.5M | 1 | 255 |
| Clinical Studies Using AstraZeneca UKs Anti Cancer Agrents Cediranib a Vascular Endothelial Growth Factor Receptor VEGF inhibitor and Olaparib a Polyadenosine 5 diphosphoribose Ploy aDP ribose Ploymerase PARP Inbihitor | $3.4M | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Ramesh Gupta, M.d, M.D | Specialist | Memphis, TN | $635,033 | $0 |
| Dr. David Horn, M.d, M.D | Internal Medicine | Philadelphia, PA | $521,885 | $0 |
| John Oppenheimer, Md, MD | Allergy | Cedar Knolls, NJ | $283,171 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $247,565 | $0 |
| Mikhail Kosiborod, Md, MD | Cardiovascular Disease | Kansas City, MO | $199,719 | $0 |
| Ira Smalberg, Md, MD | Diagnostic Radiology | Santa Monica, CA | $193,125 | $0 |
| Dr. C. Michael Neuwelt, M.d, M.D | Rheumatology | San Leandro, CA | $181,288 | $0 |
| Vipul Joshi, Md, MD | Specialist | Brandon, FL | $172,891 | $0 |
| Dr. Marilyn Pike, Md Phd, MD PHD | Internal Medicine | Boston, MA | $152,587 | $0 |
| Fernando Martinez, Md, MD | Critical Care Medicine | Worcester, MA | $147,323 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $141,582 | $0 |
| Pasi Antero Janne, Md Phd, MD PHD | Medical Oncology | Boston, MA | $136,089 | $0 |
| Peter Weller, M.d, M.D | Internal Medicine | Boston, MA | $135,350 | $0 |
| Jeffrey Kanne, M.d, M.D | Diagnostic Radiology | Madison, WI | $131,050 | $0 |
| Gary Ferguson, M.d, M.D | Internal Medicine | Livonia, MI | $118,387 | $0 |
| Dr. Joyce O'shaughnessy, Md, MD | Medical Oncology | Dallas, TX | $114,632 | $0 |
| Peter Merkel, Md, Mph, MD, MPH | Rheumatology | Radnor, PA | $110,250 | $0 |
| Gerard Criner, Md, MD | Pulmonary Disease | Philadelphia, PA | $106,894 | $0 |
| Dr. David Harpole, M.d, M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Durham, NC | $102,454 | $0 |
| Antonio Anzueto, Md, MD | Pulmonary Disease | San Antonio, TX | $101,949 | $0 |
| Michael Wechsler, Md, MD | Critical Care Medicine | Denver, CO | $100,199 | $0 |
| Dr. Stephanie Bernstein, Md, MD | Hematology & Oncology | Winchester, MA | $99,715 | $0 |
| Christopher Cooper, Md, MD | Pulmonary Disease | Los Angeles, CA | $99,322 | $0 |
| Dr. Max Rosen, Md Mph, MD MPH | Diagnostic Radiology | Worcester, MA | $98,780 | $0 |
| Dr. Richard Furie, M.d, M.D | Rheumatology | New Hyde Park, NY | $94,232 | $0 |
About AstraZeneca UK Limited
AstraZeneca UK Limited has made $572.5M in payments to 2,006 healthcare providers, recorded across 29,182 transactions in the CMS Open Payments database. In 2024, the company paid $114.9M. The top product by payment volume is IMFINZI ($98.0M).
Payments were distributed across 107 medical specialties. The top specialty by payment amount is Internal Medicine ($3.2M to 344 doctors).
Payment categories include: Food & Beverage ($310,662), Consulting ($12.8M), Research ($497.4M), Travel & Lodging ($3.1M), Royalties ($57.5M).
AstraZeneca UK Limited is associated with 3 products in the CMS Open Payments database.